Cheap, easy, plausible, and quiet — a single morning capsule for less than a streaming service, on a mechanism that genuinely matters and a human evidence base that's still thin. The wins, where they show up, are real but modest: fatigue, sleep, attention, mostly in adults past fifty who started out depleted. The catch is the gap between the marketing — which oversells — and the data, which is a handful of small trials, most of them paid for by the manufacturer.
Inside every cell, the mitochondria are the little engines that turn the food you ate into the energy currency that powers everything from squatting a barbell to forming this sentence. How many you have isn't fixed. There's a master gene switch called PGC-1α that, when it gets flipped on, tells the cell to build more. The most reliable way to flip it is exercise. The interesting thing about PQQ is that, in a Petri dish, it flips the same switch.
There's a second mechanism worth knowing about. PQQ is a redox cycler — it bounces between an oxidised and reduced form, mopping up the unstable molecules (free radicals) that damage cell components as it goes. Vitamin C does the same job and gets used up after a few cycles. PQQ can do it tens of thousands of times without falling apart. That fact is where the marketing's "thousands of times more powerful than vitamin C" claim comes from — and it's misleading, because your body uses vitamin C at gram-scale and PQQ at milligram-scale; per-molecule cycling capacity isn't the same as in-the-body effect Akagawa et al. 2016.
So the cell biology is real: a small molecule that signals "build more mitochondria" and that cleans up oxidative damage cheaply. The question is whether any of that translates into something you can feel.
What humans actually report
Petri dishes are easy. Humans are harder. Five small trials carry most of the published evidence; together they say PQQ does something — directionally consistent with the mechanism — but quietly. The effect sizes are modest, the trials are small (10 to 41 people), and most of them were paid for by Mitsubishi Chemical, the company that holds the BioPQQ patent. The one independent randomized trial was negative on its primary endpoint.
The pattern across the positive trials is consistent — people who started out tired, older, or metabolically less spry felt a small lift over weeks. The pattern across the trial set as a whole is the supplement-industry pattern: small studies, manufacturer money, modest effects, no large independent confirmation. That's not nothing, and it's not enough to bet anything important on either.
How to take it, if you take it
Every human trial that found something used 10 to 20 milligrams a day. There's no dose-response evidence telling you 30 would be better than 20, and there's no safety problem with the higher end — it just doesn't seem to do more. One capsule, morning, with or without food.
What the bottle gets wrong
Three claims show up on PQQ labels and in supplement-store marketing that don't survive contact with the actual literature.
"PQQ is a B vitamin." This one has a clean paper trail. In 2003, a paper in Nature proposed PQQ as a new mammalian vitamin Kasahara & Kato 2003. A rebuttal in the same journal, later the same year, showed the proposed PQQ-dependent human enzyme was nothing of the kind Felton & Anthony 2003. The mainstream nutrition community has treated PQQ as a non-vitamin ever since. Supplement marketing has not updated.
"Thousands of times more powerful than vitamin C." True per-molecule, in a cycling-capacity sense — PQQ can do the redox-cycling job thousands of times before degrading, vitamin C cannot. Useless as a real comparison: your body uses vitamin C at gram-scale and PQQ at milligram-scale, and the "powerful antioxidant" number on the bottle has no documented translation into a felt effect at supplement doses.
"PQQ replaces CoQ10." Or vice versa. They're not interchangeable. CoQ10 is a working part of the electron-transport chain — it carries electrons inside the mitochondria you already have. PQQ is a signal upstream of building more mitochondria. Different layers, both plausible to take, neither a substitute for the other.
Where this goes sideways
Two patterns account for most of the "I tried PQQ and felt nothing" reports.
Chasing a felt effect that isn't coming. The mechanism is a slow transcription program, not a stimulant. Increasing the dose to 40 or 60 mg looking for the lift the marketing promised won't produce it; what it will produce, at the high end, is mild stomach upset. If 20 mg for ten weeks doesn't move anything, the answer is to stop, not to escalate.
Stacking it into a pile of ten supplements and trying to attribute. If you start PQQ alongside CoQ10, magnesium, omega-3, a new sleep tracker, and a vow to walk more, you have no idea what did what. The honest test is single-variable: start PQQ, change nothing else, give it 8–12 weeks, and decide. A modest effect that's drowned in five louder co-interventions is exactly the kind of signal a sensible person walks away from.
A third pattern, less common but worth naming: expecting PQQ to fix something it has no business fixing. The trials that found things found them in tired older adults; a healthy 28-year-old getting good sleep is the population least likely to feel anything, because the mitochondrial reserve PQQ might nudge upward is already abundant. Younger and healthier is also where the negative trial Hwang et al. 2020 ran.
What you'd actually notice
Honest forecast, anchored to what the trials measured.
First few days. Nothing. There's no acute hit. The chemistry that's running in the background — inflammation markers ticking down, urinary signatures of mitochondrial activity shifting — is invisible to felt experience Harris et al. 2013. If you feel a buzz in week one, that's placebo or coincidence, not PQQ.
Six to eight weeks. If anything's going to happen, this is the window. For the reader who walked in tired — the kind of tired that has you reaching for a third coffee at 3 p.m. — the published pattern is a small, slowly-arriving lift: afternoons that don't drag as hard, sleep that comes a little easier, the bedside lamp going off ten minutes sooner Nakano et al. 2012. Nobody at the office is going to say you look different. Your partner probably won't notice. You'll notice — quietly — that the version of you that gets through the afternoon isn't quite as flattened.
Three months and beyond, past fifty. The cognitive trial in older adults Itoh et al. 2016 tracked attention and working memory — the everyday "hold this number in your head while you walk to the kitchen" task — and saw a modest improvement at twelve weeks. The felt translation is small but real: the names come back faster, the sentence in your head doesn't slip while you reach for it, the second cup of coffee buys you actual focus and not just alertness. Not a transformation, not a "new you" — a quieter floor under a kind of capacity that was starting to leak.
Years. Nobody knows. There are no long-term trials. The mechanism — supporting the same mitochondrial machinery that exercise builds — gives a plausible long-game story, but nothing in the published evidence lets you cash it out as a number on a survival curve. Treat the long horizon as "the mechanism is consistent with continued support, the outcomes are an open question."
If none of that lands at twelve weeks, the right move is to stop. A supplement whose felt effect is "I think maybe?" for months on end is one where you're paying for the maybe, not the effect.
PQQ sits in a small neighbourhood of "support the mitochondria" interventions worth knowing about together. CoQ10 is the obvious neighbour — different layer (electron transport vs. biogenesis), often taken alongside, well-trodden. Urolithin A and the NAD+ precursor family (NMN, NR) are the newer entries in the same conceptual frame; their evidence bases have similar features (mechanism strong, human trials small, manufacturer-adjacent). And the cheapest, best-evidenced mitochondrial intervention of all is still exercise — it activates the same PGC-1α pathway PQQ tickles, but at a magnitude no capsule comes close to.
1. Substance and claimed effects
Pyrroloquinoline quinone (PQQ) is a small redox-active ortho-quinone, discovered in 1979 as a cofactor for bacterial alcohol and glucose dehydrogenases. It is present in trace amounts (nanograms to low micrograms per gram) in most foods, with the highest concentrations in fermented soybeans (natto), parsley, green peppers, kiwifruit, and human milk. It is sold as a supplement in 10–20 mg/day doses, most often as the disodium salt (BioPQQ, manufactured by Mitsubishi Gas Chemical until 2018, now Mitsubishi Chemical's spin-off). Claims made for human supplementation cluster on five consequences, all of which this entry covers: mitochondrial density (PGC-1α-mediated biogenesis), daily energy and reduced fatigue, cognitive performance in older adults, sleep quality and onset, and oxidative-stress / inflammation markers Akagawa et al. 2016. The substance is also pitched as a cofactor stack-mate to CoQ10 — sharing the mitochondrial-electron-transport-chain frame — though the two work at different levels (biogenesis vs. ATP production).
Whether PQQ is a vitamin in mammals was the subject of an unusually high-profile dispute in Nature: Kasahara and Kato proposed it as a new B-vitamin in 2003 Kasahara & Kato 2003; Felton and Anthony's rebuttal the same year showed the proposed mammalian PQQ-dependent enzyme (AASDH) does not in fact use PQQ as a cofactor Felton & Anthony 2003. The settled view: PQQ is not a vitamin. It is a redox-active small molecule with some bioactivity at supraphysiological doses, distinct from its essential-cofactor role in bacteria.
2. Evidence by addressing question
Mechanism
Science. The cornerstone mechanism finding is Chowanadisai et al. 2010: in mouse hepatocytes and 3T3 fibroblasts, PQQ at low micromolar concentrations activated CREB phosphorylation, which in turn upregulated PGC-1α, the master transcriptional regulator of mitochondrial biogenesis Chowanadisai et al. 2010. Downstream they observed increased mitochondrial DNA copy number, increased citrate synthase activity, and increased oxygen consumption. The PGC-1α pathway is the same pathway exercise activates, which is the basis for the "exercise mimetic" framing in supplement marketing — though the magnitude is not comparable.
Mechanism. Two complementary mechanisms: (i) PQQ is a redox cofactor that cycles between oxidised and reduced forms, scavenging superoxide and hydroxyl radicals; unlike vitamin C or glutathione it can cycle tens of thousands of times without degradation, making per-molecule radical-quenching capacity high. (ii) The CREB → PGC-1α → mitobiogenesis cascade is the genomic mechanism. In vivo, Stites et al. 2006 fed mice PQQ-replete vs. PQQ-deficient diets and showed deficient animals had fewer mitochondria per hepatocyte and lower mitochondrial respiratory function; resupplementation reversed it Stites et al. 2006. The "deficiency" framing is contested — see §3 — but the mitobiogenesis effect itself replicates in independent cell and rodent work Akagawa et al. 2016.
Limit. The translation gap from rodent / cell-line PGC-1α activation to functional human outcomes is the central unresolved question. Mitochondrial density in humans on PQQ has not been directly measured (muscle biopsy or PET) in any published trial; the human studies infer mitochondrial engagement from urinary metabolite shifts and from inflammation markers Harris et al. 2013.
Evidence
Science. Five human trials carry most of the evidence weight, all of them small:
- Harris et al. 2013 — crossover, 10 healthy adults, 0.2 mg/kg (≈14 mg for a 70 kg adult) for 72 hours. Plasma CRP fell, IL-6 fell, urinary metabolite analysis showed shifts in TCA-cycle and methylated amine metabolites consistent with altered mitochondrial-related metabolism. No clinical outcome, just biomarker shifts. NMR methods, single-site, no placebo arm in the classical sense (within-subject crossover) Harris et al. 2013.
- Nakano et al. 2012 — open-label, 17 adults with self-reported fatigue / poor sleep, BioPQQ 20 mg/day for 8 weeks. POMS (Profile of Mood States) scores improved on vigour, fatigue, and tension/anxiety subscales; OSA-MA sleep questionnaire improved on sleep onset and duration. No blinding, no placebo arm, open-label industry-funded Nakano et al. 2012.
- Itoh et al. 2016 — double-blind RCT, 41 older adults (~50–70), BioPQQ 20 mg/day vs. placebo for 12 weeks. Cognitive function battery (Stroop, verbal memory, spatial cognition) improved on selected subscales in the PQQ arm; the effect was most consistent on tests of attention and working memory. fNIRS measurements of prefrontal cortex activation also shifted Itoh et al. 2016.
- Koikeda et al. 2011 (Japanese-language, often cited in English reviews) — older adults, PQQ vs. placebo, cognitive improvement on Stroop test. Summarised in Akagawa et al. 2016.
- Hwang et al. 2020 — RCT, 18 untrained men, PQQ 20 mg/day vs. placebo for 6 weeks of aerobic training. PQQ did not outperform placebo on VO2max or time-to-exhaustion, and did not increase circulating markers of mitochondrial biogenesis (PGC-1α, irisin, FNDC5). One of the few negative trials, and one of the few not industry-funded Hwang et al. 2020.
Effect sizes across the positive trials are modest — subscale improvements within questionnaires, biomarker shifts of single-digit percentage magnitude, no transformative results. Sample sizes are small (N=10–41). Most positive trials use BioPQQ specifically and were funded directly or indirectly by Mitsubishi Gas Chemical; the one independently-funded RCT (Hwang) was negative on its primary endpoint.
Mechanism. The mechanistic evidence is far stronger than the human-outcome evidence: PGC-1α activation, mitobiogenesis in cell culture and rodent models, redox cycling are all replicated across independent labs Akagawa et al. 2016. The disconnect between mechanism-rich and outcome-thin is the dossier's central tension.
Protocol
Science. Human trials cluster around 10–20 mg/day, taken once daily, usually morning, with or without food. Harris 2013 used 0.2 mg/kg (≈14 mg for a 70 kg adult); Nakano 2012, Itoh 2016, and Hwang 2020 all used 20 mg/day. No dose-response trial has been run in humans; the 20 mg figure derives from Mitsubishi's product development, not from a derived no-observed-adverse-effect-level calculation.
Practice. Supplement-community dosing is in the same 10–20 mg/day range, occasionally up to 40 mg/day. PQQ is often paired with CoQ10 (typically 100–200 mg ubiquinol or ubiquinone) on the theory that PQQ drives biogenesis (more mitochondria) while CoQ10 supports electron-transport-chain function in the mitochondria that exist. The combination is theoretically sensible; no trial has directly tested PQQ alone vs. PQQ+CoQ10 vs. CoQ10 alone on any outcome.
Contraindications
Science. No serious adverse events reported in any published human trial. Doses up to 60 mg/day for 4 weeks tolerated in safety studies Akagawa et al. 2016. Mild GI upset (loose stools, nausea) reported anecdotally at higher doses (>40 mg).
Practice. Pregnancy and breastfeeding: PQQ is present in human breast milk and animal studies suggest dietary role in reproductive function Stites et al. 2006, but no human safety trials have been conducted in pregnancy or lactation — standard supplement caution applies (avoid in absence of obstetric clearance). No documented interactions with common medications, though formal drug-interaction studies are absent.
Misconceptions
Practice. The widespread "PQQ is a B vitamin" claim, repeated across supplement marketing, traces to Kasahara & Kato's 2003 Nature brief Kasahara & Kato 2003. Felton & Anthony's same-year rebuttal demonstrated the proposed mammalian PQQ-dependent enzyme was not in fact PQQ-dependent Felton & Anthony 2003. The "vitamin" label has persisted in marketing despite being false; PQQ is a bioactive food component, not a vitamin.
Second misconception: PQQ is sometimes pitched as a replacement for CoQ10 (or vice versa). They are not interchangeable. CoQ10 is an electron-transport-chain component (ubiquinone Q10); PQQ is a transcriptional signal upstream of mitobiogenesis. Different layers.
Third: the "5,000× more powerful antioxidant than vitamin C" claim in marketing materials is based on per-molecule cycling capacity, not on in-vivo antioxidant effect. In a body where vitamin C is consumed at gram-scale daily and PQQ at milligram-scale, the comparison is apples-to-oranges.
Practicalities
Practice. Retail cost runs $15–35/month for 10–20 mg/day capsules, depending on brand. BioPQQ (Mitsubishi-licensed) commands a premium over generic sources. Stability in capsule form is good; refrigeration not required. The supplement industry's typical caveats apply: third-party tested products (USP, NSF, ConsumerLab) reduce sourcing risk, especially as PQQ became cheaper to synthesise post-2015 and generic supply expanded.
Payoff
Science. If supplementation works, the felt effect across positive trials is modest and slow: subjective fatigue and sleep improvements over 6–8 weeks Nakano et al. 2012; subtle cognitive shifts in older adults over 12 weeks Itoh et al. 2016; biomarker shifts in CRP and TCA-cycle metabolites within days Harris et al. 2013. No published trial has shown the kind of overt felt-experience shift caffeine, exercise, or sleep restriction reversal produce. The honest payoff frame is "a small additional mitochondrial nudge, plausibly real, modest in magnitude, slow to land."
Failure modes
Practice. Two patterns from community reports: (i) overdosing in pursuit of a felt effect — increasing dose to 40–60 mg looking for the "energy" the marketing promised, which doesn't materialise and may cause mild GI distress; (ii) stacking PQQ with caffeine, nootropics, and 10+ other supplements such that any signal from PQQ is unidentifiable. The reasonable test is single-variable: PQQ alone, 8–12 weeks, decide whether to continue.
3. The credibility range
The optimist case
The mechanism is real and replicated. PQQ activates CREB → PGC-1α → mitochondrial biogenesis across independent labs and model systems Chowanadisai et al. 2010, Stites et al. 2006. The same PGC-1α pathway is what exercise activates; the same mitochondrial-density gain underlies endurance training adaptation. PQQ is one of the few small molecules with documented mitobiogenic action and an excellent safety profile across human dosing. Five small human trials show consistent (if modest) directional signal: reduced inflammation markers, improved sleep, improved fatigue, improved cognition in older adults. The negative trial (Hwang 2020) was a young, healthy, training population — exactly where mitochondrial reserve is already abundant and an exogenous biogenic signal has the least headroom; absence of effect there does not refute effect in older or metabolically compromised populations. At ~$20/month and a single capsule a day, the cost-benefit for the modest expected gain is favourable, and downside risk across the published safety data is near-zero. The reasonable position: take it, especially over 40 or 50.
The skeptic case
Mechanism in a Petri dish does not entail benefit in a human. The actual human evidence is five small trials, four of them industry-funded, three of them open-label or quasi-experimental, with effect sizes that hover at the edge of statistical detectability. The one independent RCT (Hwang 2020) was negative Hwang et al. 2020. No trial has directly measured mitochondrial density or function in humans on PQQ; mitobiogenesis is inferred from urinary metabolites and inflammation proxies. The supplement is marketed with the discredited "B-vitamin" framing Felton & Anthony 2003 and the wildly misleading "5,000× vitamin C antioxidant" comparison; both are red flags about the surrounding ecosystem. The supplement-industry pattern (small Japanese trials, manufacturer involvement, modest endpoints, no replication outside the manufacturer's orbit) is the same pattern that has produced decades of disappointing CoQ10, NADH, alpha-lipoic-acid, and resveratrol stories — strong mechanism, weak human outcomes, modest commercial momentum. The reasonable position: skip it; the same $200/year buys better dietary fish oil, magnesium, or a creatine supply, all of which have stronger human evidence.
The author's call
The mechanism is too well-replicated to dismiss and the human evidence is too thin to endorse loudly. The honest reading: PQQ is a low-magnitude, plausibly-real, slow-onset mitochondrial nudge with a clean safety profile and a real overhype problem in its marketing. Worth trying for the reader specifically interested in mitochondrial supports — particularly past 40, where mitochondrial decline is real and any biogenic signal has more headroom; the existing trials cluster in that population. Not worth recommending broadly; not worth taking instead of the bigger-lever interventions (exercise, sleep, protein-and-creatine for muscle, omega-3 for inflammation). Score `evidence` at 2 (sparse, mostly small Japanese trials, mechanism strong but human outcomes thin) and `controversy` at 2 (real disagreement between mechanism-credulous and outcome-skeptical readings of the same data, but no foundational paradigm fight).
4. Stakeholder and incentive map
- Commercial — Mitsubishi Chemical and BioPQQ licensees. The single largest commercial incentive. Mitsubishi developed the disodium-salt form, holds (or held) patents on the production process, and licenses BioPQQ to most major US supplement brands. Most of the positive human trials are direct or indirect Mitsubishi-funded work.
- Commercial — generic PQQ producers. Post-2015 the price of synthesised PQQ fell substantially; Chinese generic supply now competes with BioPQQ at lower prices. The generic market amplifies marketing claims (since they cannot match BioPQQ's trial-citation set) and is the source of much of the "5,000× vitamin C" hyperbole.
- Academic — the Rucker lab at UC Davis and a small set of independent collaborators have produced the foundational rodent and cell-culture mechanism work Chowanadisai et al. 2010, Stites et al. 2006, Harris et al. 2013. The Rucker group's framing of PQQ as a "nutritionally important factor" is more cautious than the marketing extension but more credulous than the mainstream nutrition community.
- Wellness and longevity influencers — recurring promoters in the "mitochondrial health" subgenre (CoQ10, urolithin A, NMN, NR, MitoQ stacks). PQQ tends to ride this wave; the framing is uniformly bigger than the evidence supports.
- Skeptic counterweight — nutrition-science mainstream. Mainstream nutrition / clinical communities largely ignore PQQ; it does not appear in major dietary guidelines and has no regulatory status as a nutrient. The 2003 Nature rebuttal Felton & Anthony 2003 shaped the community's "interesting bacterial cofactor, irrelevant in humans" stance, which has not meaningfully updated.
5. Population variability
Three signals from the trial structure:
- Age. Itoh et al. 2016 (positive cognitive endpoint) and Koikeda et al. 2011 (positive Stroop endpoint) both used older adults (50–70). Hwang et al. 2020 (negative endpoint) used young untrained men. The age-effect heuristic — that mitochondrial reserve declines with age and an exogenous biogenic signal has more headroom in depleted systems — is consistent with the trial pattern but unproven causally.
- Baseline fatigue / sleep status. Nakano et al. 2012's positive endpoint required self-reported fatigue or poor sleep at baseline. A reader sleeping well and feeling energetic is unlikely to see the effects this trial showed; the signal lives in the deficit.
- Dietary intake. Background PQQ intake from diet (natto, parsley, kiwifruit) varies substantially across populations; Japanese fermented-food eaters likely have higher baseline intake than typical Western readers. Whether this saturates or sensitises the response is unknown.
No published trials have been done in pregnancy, in clinical mitochondrial disease populations, in children, or in specific neurodegenerative populations (Parkinson's, Alzheimer's) where PQQ's mechanism would be most interesting.
6. Knowledge gaps
- No direct measurement of mitochondrial density in humans on PQQ. Muscle biopsy with mitochondrial DNA quantification, or ³¹P-MRS for in-vivo mitochondrial function, would settle the central mechanism-to-outcome translation question. Neither has been done.
- No large RCT. Largest published trial is N=41 (Itoh 2016). A 200–500-person RCT in the trial population most likely to respond (older adults with self-reported fatigue) on a hard endpoint (objective sleep, objective cognition, mitochondrial function) would be decisive.
- No replication of the cognitive findings outside the Japanese / industry-funded literature. Independent confirmation of Itoh 2016 in a non-Japanese cohort, with a non-Mitsubishi-affiliated investigator group, would substantially shift the credibility range.
- No long-term safety data. All trials are 6 weeks to 12 weeks. Multi-year supplementation safety is inferred from food-level exposure, not from formal study.
- No head-to-head with CoQ10, NMN, or NR. The mitochondrial-support supplement category has no comparative trial; readers stacking 3–4 such supplements have no basis for prioritising.
Coverage relative to brief. The brief named mitochondrial density, energy, cognition, sleep, and oxidative stress. All five are covered end to end: mitobiogenesis in mechanism, the Itoh cognitive trial in evidence and payoff, the Nakano fatigue and sleep findings in both, and oxidative stress in mechanism (redox cycling) plus evidence (Harris inflammation markers). Mood is added on top because the Nakano POMS data plainly supports it — the brief didn't name it but the dossier surfaced it.
Why no dream narrative. The honest hook is clarity, not aspiration or relief. The mechanism is real but the human evidence is thin; an aspirational "this changes your life" projection would ring false against the modest-and-quiet trial pattern, and a relief-lever ("stop paying for the thing that does nothing") would be unfair to a substance that plausibly does something. The dek and tagline are written straight per dream-narrative.md §1; overall score (~16) is well below the 40-floor that would require one.
Rating difficulties.
- energy / focus / sleep / mood all at 2. Each is supported by exactly one or two small trials with modest effect sizes. The temptation was to score them all at 1 and lean on the evidence-thinness, but that under-weights the directional consistency across the trials and the mechanism. 2 ("a real but small contribution") is the honest fit; 3 ("a meaningful, named effect") overstates.
- longevity at 1. The mechanism (PGC-1α-mediated mitobiogenesis) is one of the canonical longevity pathways, but there is zero human outcome data and inferring longevity from a Petri-dish cascade is precisely the kind of inflation the framework guards against. Held at 1.
- applicability at 2. Could plausibly be 3 if framed as "any supplement-curious reader" but the trial evidence concentrates in adults past 50 with baseline fatigue, and the marketing's reach overstates real-world relevance.
Excluded.
- Specific brand recommendations. BioPQQ is named as the trial-tested form, but pointing to a specific retailer or SKU would date faster than the article and isn't this entry's job.
- Clinical mitochondrial disease. PQQ has been discussed informally in mitochondrial-disease patient communities; no published trial in that population. Out of scope for a general-audience supplement entry; would need its own write-up if evidence ever arrives.
- Detailed dietary-source numbers. Natto / parsley / kiwifruit content varies by source and source-of-source; flagged the food presence in the research dossier but kept it out of the article to avoid implying readers can hit supplement doses dietarily (they cannot — food-level intake is in micrograms, supplements in milligrams).
Future-link candidates. coq10 (companion mitochondrial supplement, different mechanism layer), urolithin-a (mitophagy frame), nmn / nr (NAD+-precursor frame), exercise-aerobic (the PGC-1α activator everything else is compared to). Wire up related once those exist.
Separate-entry candidates. None — PQQ's scope is tight enough to live in one entry. The CoQ10/PQQ stacking question could become its own entry if and when a head-to-head trial exists; today it's just the natural pairing pattern, not a researchable topic.
Author's-call sensitivity. If a 200+ person independent RCT in older adults replicated Itoh 2016's cognitive endpoint, the right move would be to lift focus to 3 and evidence to 3. If a second negative trial like Hwang 2020 landed, the right move would be to drop energy and sleep to 1 and consider whether the entry should land as a soft "skip." Today's call sits between those two updates.
PQQ (Pyrroloquinoline Quinone)
Cheap. Roughly $15–35 a month, less than a streaming service.
One capsule in the morning. That's it.
Small, real wellness nudge — lower inflammation markers, slightly less drag — that lands quietly over weeks, not days.
Modest reduction in everyday tiredness, mostly in people who start out tired. Not caffeine-grade; a quieter dial.
Modest gains on attention and working memory, mostly in older adults. A small clarity lift, not a stimulant.
Easier to fall asleep and slightly more of it, mostly for people whose sleep is already poor.
A quiet lift in everyday tension and vigour over a couple of months. Subtle, real, not antidepressant-grade.
A handful of small human trials, most of them industry-funded; mechanism in animals is strong, human translation is thin.
Plausible long-game lever via the same mitochondrial-growth pathway exercise uses, but with no long-term human outcome data yet.